Your browser doesn't support javascript.
loading
Association of Cannabis Legalization with Cannabis Positive Drug Screening in US Veterans.
Fink, David S; Samples, Hillary; Malte, Carol A; Olfson, Mark; Wall, Melanie M; Alschuler, Daniel M; Saxon, Andrew J; Hasin, Deborah S.
Afiliación
  • Fink DS; New York State Psychiatric Institute.
  • Samples H; Rutgers Institute for Health, Healthcare Policy and Aging Research.
  • Malte CA; Health Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs Puget Sound Health Care System.
  • Olfson M; Center of Excellence in Substance Addiction Treatment and Education, VA Puget Sound Health Care System.
  • Wall MM; Columbia University Irving Medical Center.
  • Alschuler DM; New York State Psychiatric Institute.
  • Saxon AJ; Columbia University Irving Medical Center.
  • Hasin DS; New York State Psychiatric Institute.
medRxiv ; 2023 Dec 09.
Article en En | MEDLINE | ID: mdl-38105937
ABSTRACT

Background:

Although cannabis legalization is associated with increases in self-report cannabis use, biological measures of cannabis use are needed to address potential bias introduced by improved self-reporting of cannabis use in states enacting medical cannabis laws (MCL) and recreational cannabis laws (RCL).

Objective:

Quantify the role of MCL and RCL enactment in cannabis positive urine drug screen (UDS) prevalence among Veterans Health Administration (VHA) emergency department (ED) patients from 2008 to 2019.

Design:

Staggered-adoption difference-in-difference analysis were used to estimate the role of MCL and RCL in cannabis positive UDS data, fitting adjusted linear binomial regression models to estimate the association between MCL and RCL enactment and prevalence of cannabis positive UDS.

Participants:

VHA enrolled veterans aged 18-75 years with ≥1 ED visit in a given year from 2008 to 2019. Main

Measures:

Receipt of ≥1 cannabis positive UDS during an ED visit were analyzed. Key

Results:

From 2008 to 2019, adjusted cannabis positive UDS prevalences increased from 16.4% to 25.6% in states with no cannabis law, 16.6% to 27.6% in MCL-only enacting states, and 18.2% to 33.8% in RCL-enacting states. MCL-only and MCL/RCL enactment was associated with a 0.8% (95% CI, 0.4-1.0) and 2.9% (95% CI, 2.5-3.3) absolute increase in cannabis positive UDS, respectively. Significant effect sizes were found for MCL and RCL, such that 7.0% and 18.5% of the total increase in cannabis positive UDS prevalence in MCL-only and RCL states could be attributed to MCLs and RCLs.

Conclusions:

In this study of VHA ED patients, MCL and RCL enactment played a significant role in the overall increases in cannabis positive UDS. The increase in a biological measure of cannabis use reduces concerns that previously documented increases in self-reported cannabis use from surveys are due to changes in patient willingness to report use as it becomes more legal.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: MedRxiv Año: 2023 Tipo del documento: Article Pais de publicación: Estados Unidos